This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

[MedTech]+[Progress]: VectorX CRISPR In Vivo Gene Editing Delivery System Achieves Permanent Hereditary Liver Disease Repair with Single Injection

The VectorX lipid nanoparticle delivery system, jointly developed by Bayer and Beam Therapeutics, enables precise in vivo delivery of CRISPR gene editing tools, with a single intravenous injection capable of permanently repairing pathogenic gene mutations in liver cells.

Article Body

The clinical translation of gene editing technology faces a core bottleneck: how to precisely deliver CRISPR tools to the organs and cells that need repair. Most current gene editing therapies require extracting a patient's cells for ex vivo editing before reinfusion—a complex and costly process. The VectorX system is attempting to change this paradigm.

VectorX was jointly developed by Germany's Bayer Group and US-based Beam Therapeutics, with Phase I/II clinical trial results published in the New England Journal of Medicine in May 2030. The system uses proprietary lipid nanoparticles to deliver base editors directly to liver cells, achieving permanent repair of target genes through a single intravenous injection.

In clinical trials for transthyretin amyloidosis, 30 patients treated with VectorX experienced an average 93% reduction in serum pathogenic protein levels within 12 weeks of injection, with 18 patients dropping to undetectable levels. More critically, this gene repair is permanent—during 18 months of follow-up, all patients maintained stable pathogenic protein levels.

Beam Therapeutics CEO John Evans said: "VectorX's core innovation lies in the targeted ligand design of the lipid nanoparticles. We modified the particle surface with a peptide that specifically recognizes liver cell surface receptors, ensuring over 95% of nanoparticles are taken up by liver cells rather than other organs."

However, VectorX can currently only target the liver. For gene delivery to the brain, heart, lungs, and other organs, lipid nanoparticle penetration efficiency remains insufficient. Bayer's gene therapy lead stated that the team is developing next-generation delivery vehicles for the central nervous system and skeletal muscle, expected to enter clinical trials in 2032.

In terms of pricing, Beam indicated that VectorX treatment would be priced between $1.5 million and $2 million, comparable to existing marketed gene therapies. Bayer is negotiating outcome-based payment schemes with healthcare insurance agencies in multiple countries.